期刊文献+

凝结芽孢杆菌在胃肠道疾病治疗中的应用进展

Advances in the application of Bacillus coagulans in treatment of gastrointestinal diseases
下载PDF
导出
摘要 凝结芽胞杆菌(Bacillus coagulans)是一种能够产生芽孢的益生菌,由于稳定性好,在医药、食品、化工等方面具有较广泛应用。动物毒理试验和大量临床观察显示,凝结芽胞杆菌具有安全性良好、无毒副作用等优点。近年的研究显示,凝结芽胞杆菌通过改善微生态、调节机体免疫,对胃肠道疾病如急性腹泻、肠易激综合征、抗生素相关性腹泻、便秘等均有一定的治疗效果。 Bacillus coagulans is a type of probiotics that can produce endospores,and it is widely used in the fields of medicine,food,and chemical industry due to its high stability.A large number of toxicological tests and clinical observations have shown that B.coagulans has the advantages of good safety non-toxic side effeds and so on.Recent studies have shown that B.coagulans exerts a certain therapeutic effects on gastrointestinal diseases such as acute diarrhea,irritable bowel syndrome,antibiotic-associated diarrhea,and constipation by improving microecology and regulating immunity.
作者 穆媛媛 丛延广 MU Yuan-yuan;CONG Yan-guang(Department of Gastroenterology,Liaohe Oilfield Gem Flower Central Hospital,Panjin 124010,China;Preci-sion Medicine Center,Affiliated T.C.M Hospital of Southwest Medical University,Luzhou 646000,China)
出处 《西南医科大学学报》 2021年第4期404-407,共4页 Journal of Southwest Medical University
基金 国家自然科学基金(81974299) 西南医科大学-西南医科大学附属中医医院联合项目(2018XYLH-017)。
关键词 益生菌 凝结芽胞杆菌 消化系统疾病 Probiotics Bacillus coagulans Gastrointestinal disease
  • 相关文献

参考文献3

二级参考文献40

  • 1Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977; 31: 107-133.
  • 2Hemmi H,Takeuchi O,Kawai T,Kaisho T,Sato S,Sanjo H, Matsumoto M,Hoshino K,Wagner H,Takeda K,Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745.
  • 3Nell S,Suerbaum S,Josenhans C. The impact of the microbi- ota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol 2010; 8: 564-577.
  • 4Frank DN,St Amand AL,Feldman RA,Boedeker EC, Harpaz N,Pace NR. Molecular-phylogenetic characteriza- tion of microbial community imbalances in human inflam- matory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785.
  • 5Vijay-Kumar M,Aitken JD,Carvalho FA,Cullender TC, Mwangi S,Srinivasan S,Sitaraman SV,Knight R,Ley RE, Gewirtz AT. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328: 228-231.
  • 6Endres JR,Qureshi I. Probiotics for symptoms of IBS: A re- view of controlled trials. Nat Med J 2009; 1: 1-5.
  • 7Endres JR,Clewell A,Jade KA,Farber T,Hauswirth J, Schauss AG. Safety assessment of a proprietary preparation of a novel Probiotic,Bacillus coagulans,as a food ingredient. Food Chem Toxicol 2009; 47: 1231-1238.
  • 8Mazmanian SK,Round JL,Kasper DL. A microbial symbio- sis factor prevents intestinal inflammatory disease. Nature 2008; 453: 620-625.
  • 9Ochoa-Repáraz J,Mielcarz DW,Wang Y,Begum-Haque S,Dasgupta S,Kasper DL,Kasper LH. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol 2010; 3: 487-495.
  • 10Troy EB,Kasper DL. Beneficial effects of Bacteroides fragilis polysaccharides on the immune system. Front Biosci 2010; 15: 25-34.

共引文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部